Business Context and Reporting Period
Company: EyePoint Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 22, 2018 (Earliest event reported)
Reporting Period: Events occurring between June 22, 2018, and June 26, 2018.
The filing details the closing of a significant equity financing transaction, the advancement of a term loan, the appointment of a new director, and the results of a Special Meeting of Stockholders.
Key Financial Metrics and Capital Structure
- Equity Financing (Second Tranche Transaction):
- Gross Proceeds: Approximately $25.5 million.
- Securities Issued: 20,184,224 Units (each consisting of one share of Common Stock and one warrant).
- Purchase Price: $1.265 per Unit.
- Warrant Terms: Exercise price is the lower of $1.43 or a 20% discount to the 20-day VWAP (floor of $0.88). Warrants are exercisable until the 15th business day following notice of a new C-Code for DEXYCU.
- Debt Financing (Credit Agreement):
- Total Loan Capacity: $20 million senior secured term loan.
- Initial Advance: $15 million (advanced March 28, 2018).
- Additional Advance: $5 million (advanced June 26, 2018, contingent on the equity raise).
- Interest Rate: 3-month LIBOR (1.5% floor) + 10.50%.
- Maturity Date: March 28, 2023.
- Use of Proceeds: Working capital and funding the commercialization of DEXYCU and, if approved, YUTIQ.
Material Changes and Corporate Actions
- Capital Raise: The company successfully raised approximately $25.5 million in equity and secured an additional $5 million in debt, satisfying the "Minimum Capital Raise" requirement for the full term loan.
- Board Composition: Göran Ando, M.D., was appointed to the Board of Directors and the Science Committee. He received an option to purchase 80,000 shares and an annual retainer of $44,000.
- Authorized Shares: Stockholders approved an amendment to increase authorized Common Stock from 120,000,000 to 150,000,000 shares.
- Warrant Exercise Rights: 77,721 shares underlying the SWK Warrant became exercisable on June 26, 2018, following the Additional Advance.
Outlook, Risks, and Contingencies
- Commercialization Focus: Management intends to use proceeds specifically for the commercialization of DEXYCU and potential FDA-approved YUTIQ.
- Warrant Exercise Contingency: The Second Tranche Warrants have a unique exercise window tied to the Centers for Medicare & Medicaid Services (CMS) establishing a new C-Code for DEXYCU.
- Registration Rights: The company is required to file a shelf registration statement within 30 days of the closing to register the resale of securities issued to Second Tranche Investors.
- Unregistered Securities: Securities were sold pursuant to Section 4(a)(2) and Rule 506 exemptions; they are restricted and cannot be resold without registration or an exemption.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the status of the CMS C-Code for DEXYCU, as this triggers the warrant exercise period.
- Review the full text of the Credit Agreement (Exhibit 10.4) for covenants and default provisions.
- Monitor the filing of the shelf registration statement required within 30 days of June 25, 2018.
- Check for any subsequent filings regarding the FDA approval status of YUTIQ.